The CCR2-CCR5 antagonist, cenicriviroc, which blocks chemotactic signaling of CCL2 (MCP-1), CCL3 and 4 (MIP-1α and β), and CCL5 (RANTES), showed encouraging phase 2b study results of improving fibrosis without worsening NASH activity and a phase 3 study is currently under way. This evidence concerns the gene CCL2 and metabolic dysfunction-associated steatohepatitis.